Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MYRBETRIQ®/MYRBETRIQ® GRANULES safely and effectively. See full prescribing information for MYRBETRIQ/MYRBETRIQ GRANULES. MYRBETRIQ (mirabegron extended-release tablets), for oral useMYRBETRIQ GRANULES (mirabegron for extended-release oral suspension)Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
MYRBETRIQ Monotherapy MYRBETRIQ® is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. MYRBETRIQ Combination Therapy with Solifenacin Succinate MYRBETRIQ, in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. MYRBETRIQ Granules MYRBETRIQ® Granules is indicated for the treatment of NDO in pediatric patients aged 3 years and older. MYRBETRIQ MYRBETRIQ is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.
- generic_name
- mirabegron
- product_names
- mirabegron
- ndc
- 0469-2601, 0469-2602, 0469-5020, 0469-2601-30, 0469-2601-90, 0469-2601-07, 0469-2602-30, 0469-2602-90, 0469-2602-07, 0469-5020-99
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en